{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+Placebo-Control+Arm+0.9%25+Sodium+Chloride&page=2",
    "query": {
      "intervention": "Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 275,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+Placebo-Control+Arm+0.9%25+Sodium+Chloride&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+Placebo-Control+Arm+0.9%25+Sodium+Chloride&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T12:07:04.695Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07219459",
      "title": "Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Unresectable or Metastatic Hepatocellular Carcinoma",
        "Child-Pugh A Hepatocellular Carcinoma",
        "Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound"
      ],
      "interventions": [
        {
          "name": "Visugromab RDE (recommended dose for expansion)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo Saline Infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "CatalYm GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 104,
      "start_date": "2026-03-19",
      "completion_date": "2031-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 6,
      "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 3 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219459"
    },
    {
      "nct_id": "NCT02479789",
      "title": "Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thyroidectomy",
        "Nerve Monitoring"
      ],
      "interventions": [
        {
          "name": "Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bronx-Lebanon Hospital Center Health Care System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 66,
      "start_date": "2015-06",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2018-02-22",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02479789"
    },
    {
      "nct_id": "NCT03985982",
      "title": "Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Frown Lines"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Croma-Pharma GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 410,
      "start_date": "2019-04-29",
      "completion_date": "2020-12-22",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03985982"
    },
    {
      "nct_id": "NCT02725957",
      "title": "A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer Subjects"
      ],
      "interventions": [
        {
          "name": "Trehalose for IV Infusion",
          "type": "DRUG"
        },
        {
          "name": "Saline 0.9% IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioblast Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-03",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-11-22",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02725957"
    },
    {
      "nct_id": "NCT03222973",
      "title": "Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BIIB033 (opicinumab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "58 Years",
        "sex": "ALL",
        "summary": "18 Years to 58 Years"
      },
      "enrollment_count": 263,
      "start_date": "2017-11-15",
      "completion_date": "2021-02-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 51,
      "location_summary": "Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03222973"
    },
    {
      "nct_id": "NCT06376916",
      "title": "Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tachycardia Atrial",
        "Atrial Fibrillation",
        "Atrial Flutter With Rapid Ventricular Response"
      ],
      "interventions": [
        {
          "name": "Magnesium Sulfate 2 G",
          "type": "DRUG"
        },
        {
          "name": "Magnesium Sulfate 4 G",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2024-10-07",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 1,
      "location_summary": "Oak Lawn, Illinois",
      "locations": [
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06376916"
    },
    {
      "nct_id": "NCT04471038",
      "title": "Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza Type A",
        "Influenza Type B",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "SAB-176",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 27,
      "start_date": "2020-07-29",
      "completion_date": "2021-04-19",
      "has_results": true,
      "last_update_posted_date": "2025-01-06",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04471038"
    },
    {
      "nct_id": "NCT04799249",
      "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "TNBC - Triple-Negative Breast Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2021-05-14",
      "completion_date": "2024-05-24",
      "has_results": false,
      "last_update_posted_date": "2024-08-01",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Clinton",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04799249"
    },
    {
      "nct_id": "NCT00925548",
      "title": "STRIDE - STimulating Immune Response In aDvanced brEast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Tecemotide (L-BLP25) and Hormonal Treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo of tecemotide (L-BLP25) and Hormonal Treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "sodium chloride (NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2009-09",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 1,
      "location_summary": "Hickory, North Carolina",
      "locations": [
        {
          "city": "Hickory",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00925548"
    },
    {
      "nct_id": "NCT03389555",
      "title": "Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Sepsis",
        "Septic Shock",
        "Metabolic Disturbance"
      ],
      "interventions": [
        {
          "name": "vitamin C, vitamin B1, hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2018-02-09",
      "completion_date": "2020-02-28",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-10-10T12:07:04.695Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03389555"
    }
  ]
}